Van Thuong Nguyen, Minh Trang Trinh, Huu Doanh Le, Huu Sau Nguyen, Thanh Tung Vu, Huu Nghi Dinh, Cam Van Tran, Huyen My Le, Hau Khang Tran, Trong Hao Nguyen, Gandolfi Marco, Satolli Francesca, Feliciani Claudio, Tirant Michael, Vojvodic Aleksandra, Lotti Torello
National Hospital of Dermatology and Venereology, Hanoi, Vietnam.
HCMC Hospital of Dermato-Venereology, Ho Chi Minh City, Vietnam.
Open Access Maced J Med Sci. 2019 Jan 29;7(2):283-286. doi: 10.3889/oamjms.2019.095. eCollection 2019 Jan 30.
Vitiligo is an acquired pigmentary disease, that causes progressive loss of melanocytes, resulting in hypopigmented skin patches. Current treatments aim at stopping the disease progression and achieving repigmentation of the amelanotic areas. Corticosteroids, surgery, topical immunomodulators, total depigmentation of normal pigmented skin and phototherapy are current treatment options for vitiligo although phototherapy remains the treatment of choice. There is no documented evidence that herbal bio-active products may also be effective treatment options for vitiligo.
This study aimed to investigate the efficacy and safety of Vitilinex® (herbal bio- actives) alone and in combination with UVB narrowband (311 nm) phototherapy, in the treatment of localised stable or active forms of vitiligo.
Sixty two subjects with mean age 34.5 years (range: 18-58 years) with mild to moderate vitiligo, consisting of 36 females and 26 males were randomly divided into three treatment groups - Group A (13 females, 10 males) treated with Vitilinex® alone; Group B (12 females, 11 males) were treated with Vitilinex® in combination with narrowband UVB (311 nm) phototherapy for 15 seconds, using a handheld lamp and Group C (8 females, 8 males) were treated with nbUVB (311 nm) phototherapy alone, for 15 seconds over a 12-week period.
In Group A, 9 patients (39%) achieved outstanding improvement with a re-pigmentation rate higher than 75%, with 2 patients experiencing total repigmentation. 6 patients (26%) had marked improvement with a repigmentation rate between 50-75% while 5 patients (22%) showed a moderate response between 25-50% re-pigmentation rate. 3 patients (13%) had minimal or no improvement. In Group B, 16 patients (69.5%) achieved outstanding improvement with a re-pigmentation rate higher than 75%, with 12 patients experiencing total re-pigmentation. 4 patients (17.5 %) achieved a marked improvement with a re-pigmentation rate between 50-75%; 2 patients (8.7%) showed a moderate response with a re-pigmentation rate between 25-50%. 1 (4.3%) patient had minimal or no improvement. In Group C, 6 patients (37.5%) achieved a re-pigmentation rate higher than 75%, with 2 patients experiencing total re-pigmentation. 4 patients (25%) achieved marked improvement with a re-pigmentation rate between 50-75% while 3 patients (18.75%) had a re-pigmentation rate between 25-50%. 3 patients (18.75%) had minimal or no improvement.
Vitilinex® herbal bio-actives in combination with nbUVB is a more effective treatment option for vitiligo with 87% of the patients achieving a re-pigmentation rate higher than 50%, compared to Vitilinex® alone (65%) or nbUVB alone (62.5%).
白癜风是一种获得性色素沉着疾病，会导致黑素细胞进行性丧失，从而形成皮肤色素减退斑。目前的治疗旨在阻止疾病进展并使无色素区域重新色素沉着。皮质类固醇、手术、局部免疫调节剂、正常色素皮肤的完全脱色以及光疗是目前白癜风的治疗选择，尽管光疗仍是首选治疗方法。尚无文献证据表明草药生物活性产品可能也是白癜风的有效治疗选择。
本研究旨在调查维蒂利克斯（草药生物活性物质）单独使用以及与窄谱中波紫外线（311nm）光疗联合使用，治疗局限性稳定型或活动型白癜风的疗效和安全性。
62名平均年龄34.5岁（范围：18 - 58岁）的轻度至中度白癜风患者，其中36名女性和26名男性，被随机分为三个治疗组——A组（13名女性，10名男性）仅用维蒂利克斯治疗；B组（12名女性，11名男性）用维蒂利克斯联合窄谱中波紫外线（311nm）光疗15秒，使用手持灯；C组（8名女性，8名男性）仅用窄谱中波紫外线（311nm）光疗15秒，为期12周。
A组中，9名患者（39%）取得显著改善，色素沉着恢复率高于75%，2名患者实现完全色素沉着恢复。6名患者（26%）有明显改善，色素沉着恢复率在50 - 75%之间，而5名患者（22%）表现为中度反应，色素沉着恢复率在25 - 50%之间。3名患者（13%）改善极小或无改善。B组中，16名患者（69.5%）取得显著改善，色素沉着恢复率高于75%，12名患者实现完全色素沉着恢复。4名患者（17.5%）有明显改善，色素沉着恢复率在50 - 75%之间；2名患者（8.7%）表现为中度反应，色素沉着恢复率在25 - 50%之间。1名患者（4.3%）改善极小或无改善。C组中，6名患者（37.5%）色素沉着恢复率高于75%，2名患者实现完全色素沉着恢复。4名患者（25%）有明显改善，色素沉着恢复率在50 - 75%之间，而3名患者（18.75%）色素沉着恢复率在25 - 50%之间。3名患者（18.75%）改善极小或无改善。
维蒂利克斯草药生物活性物质联合窄谱中波紫外线是治疗白癜风更有效的选择，87%的患者色素沉着恢复率高于50%，相比之下，仅用维蒂利克斯（65%）或仅用窄谱中波紫外线（62.5%）。
